Novartis Shares Fall 10% as Del-desiran Fails Late-Stage Trial

Novartis shares fell 10% on Tuesday after the company announced that its drug del-desiran had failed in a late-stage trial for the treatment of a muscle-wasting disease. This marks the third drug trial setback for the company within a week. As of the latest trading session, Novartis shares were down 10%.